Kura Oncology to Report Third Quarter 2023 Financial Results
27 October 2023 - 7:05AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that it will report third quarter 2023 financial results after the
close of U.S. financial markets on Thursday, November 2, 2023.
Kura’s management will host a webcast and conference call at 4:30
p.m. ET / 1:30 p.m. PT that day to discuss the financial results
and provide a corporate update.
The live call may be accessed by dialing (888) 886-7786 for
domestic callers and (416) 764-8658 for international callers. A
live webcast and archived replay of the event will be available
here or online from the investor relations section of the company
website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. The Company’s
pipeline consists of small molecule drug candidates that target
cancer signaling pathways. Ziftomenib is a once-daily, oral drug
candidate targeting the menin-KMT2A protein-protein interaction for
the treatment of genetically defined acute myeloid leukemia (AML)
patients with high unmet need. Kura is currently enrolling patients
in a Phase 2 registration-directed trial of ziftomenib in
NPM1-mutant relapsed or refractory AML (KOMET-001). The Company is
also conducting a series of studies to evaluate ziftomenib in
combination with current standards of care, beginning with
venetoclax/azacitidine and standard induction
cytarabine/daunorubicin chemotherapy in NPM1-mutant and
KMT2A-rearranged newly diagnosed and relapsed/refractory AML
(KOMET-007). Tipifarnib, a potent and selective FTI, is currently
in a Phase 1/2 trial in combination with alpelisib for patients
with PIK3CA-dependent head and neck squamous cell carcinoma
(KURRENT-HN). Kura is also evaluating KO-2806, a next-generation
FTI, in a Phase 1 dose-escalation trial as a monotherapy and in
combination with other targeted therapies (FIT-001). For additional
information, please visit Kura’s website at www.kuraoncology.com
and follow us on Twitter and LinkedIn.
Contacts
Investors:Pete De SpainExecutive Vice President, Investor
Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager, Corporate
Communications(858) 500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024